Logo

New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine

Share this

New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine

Shots:

  • New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
  • Patients switching from reference biologics to biosimilar versions will continue receiving safe- effective treatment and will enable to save millions of dollars once implemented
  • Sandoz is committed to supporting patients- their HCPs- and the New Brunswick Government with high quality biosimilar medicines and experienced- comprehensive patient support programs

  Ref: Sandoz | Image: Sandoz

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions